{"id":62110,"date":"2026-04-01T21:10:26","date_gmt":"2026-04-01T13:10:26","guid":{"rendered":"https:\/\/flcube.com\/?p=62110"},"modified":"2026-04-01T21:10:27","modified_gmt":"2026-04-01T13:10:27","slug":"astrazeneca-reports-positive-phase-iii-results-for-efzimfotase-alfa-in-hypophosphatasia-across-pediatric-and-adult-populations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62110","title":{"rendered":"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations"},"content":{"rendered":"\n<p><strong>AstraZeneca<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) announced positive results from its comprehensive <strong>Phase III clinical program<\/strong> for <strong>efzimfotase alfa (ALXN1850)<\/strong>, an investigational enzyme replacement therapy (ERT) for <strong>hypophosphatasia (HPP)<\/strong>, demonstrating favorable safety and efficacy across pediatric and adult patient populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-portfolio\">Clinical Trial Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Population<\/th><th>Comparator<\/th><th>Key Results<\/th><\/tr><\/thead><tbody><tr><td><strong>MULBERRY<\/strong><\/td><td>Treatment-na\u00efve pediatric (2 to &lt;12 years)<\/td><td>Placebo<\/td><td>Statistically significant improvement in skeletal health<\/td><\/tr><tr><td><strong>CHESTNUT<\/strong><\/td><td>Pediatric switchers from Strensiq (2 to &lt;12 years)<\/td><td>Strensiq (asfotase alfa)<\/td><td>Maintained skeletal benefits with improved dosing regimen<\/td><\/tr><tr><td><strong>HICKORY<\/strong><\/td><td>Treatment-na\u00efve adolescents\/adults (\u226512 years)<\/td><td>Placebo<\/td><td>Numerical improvement in 6MWT; significant fatigue reduction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovation\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: Efzimfotase alfa (ALXN1850) \u2013 investigational enzyme replacement therapy<\/li>\n\n\n\n<li><strong>Target Indication<\/strong>: Hypophosphatasia (HPP) \u2013 rare metabolic bone disorder<\/li>\n\n\n\n<li><strong>Key Advantages<\/strong>:<\/li>\n\n\n\n<li>Lower injection volume compared to Strensiq (asfotase alfa)<\/li>\n\n\n\n<li>Less frequent dosing schedule<\/li>\n\n\n\n<li>Broader patient population coverage<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Phase III completed across multiple age groups<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-detailed-clinical-outcomes\">Detailed Clinical Outcomes<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mulberry-trial-pediatric-treatment-naive\">MULBERRY Trial (Pediatric, Treatment-Na\u00efve)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population<\/strong>: Children aged 2 to &lt;12 years with HPP<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Skeletal health improvements<\/li>\n\n\n\n<li><strong>Result<\/strong>: <strong>Statistically significant and clinically meaningful<\/strong> improvements versus placebo<\/li>\n\n\n\n<li><strong>Significance<\/strong>: First robust evidence of efficacy in treatment-na\u00efve pediatric HPP patients<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chestnut-trial-pediatric-strensiq-switchers\">CHESTNUT Trial (Pediatric, Strensiq Switchers)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population<\/strong>: Children aged 2 to &lt;12 years switching from Strensiq<\/li>\n\n\n\n<li><strong>Primary Assessment<\/strong>: Safety and tolerability<\/li>\n\n\n\n<li><strong>Secondary Endpoints<\/strong>: RGI-C (Radiographic Global Impression of Change) and RSS (Rachitic Severity Score)<\/li>\n\n\n\n<li><strong>Results<\/strong>: Well-tolerated with <strong>maintained treatment benefits<\/strong> on skeletal health at Week 25 compared to Strensiq<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hickory-trial-adolescent-adult-treatment-naive\">HICKORY Trial (Adolescent\/Adult, Treatment-Na\u00efve)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population<\/strong>: Patients aged 12 years and older with HPP<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Six-minute walk test (6MWT) at Week 25<\/li>\n\n\n\n<li><strong>Result<\/strong>: Numerical improvement that <strong>did not reach statistical significance<\/strong> due to higher-than-expected placebo performance<\/li>\n\n\n\n<li><strong>Secondary Endpoint<\/strong>: FACIT-Fatigue scale showed <strong>nominally significant improvements<\/strong> in overall study population<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HPP Prevalence<\/strong>: Ultra-rare disease affecting approximately 1 in 100,000 live births<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Strensiq (asfotase alfa) \u2013 Alexion&#8217;s (now AstraZeneca) existing ERT requiring frequent, high-volume injections<\/li>\n\n\n\n<li><strong>Unmet Needs<\/strong>:<\/li>\n\n\n\n<li>Improved convenience through reduced injection burden<\/li>\n\n\n\n<li>Expanded access to adolescent and adult populations<\/li>\n\n\n\n<li>Better tolerability profile<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Orphan drug designation likely to provide market exclusivity and premium pricing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-for-astrazeneca\">Strategic Significance for AstraZeneca<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare Disease Franchise<\/strong>: Strengthens AstraZeneca&#8217;s position in ultra-rare metabolic disorders following Alexion acquisition<\/li>\n\n\n\n<li><strong>Lifecycle Management<\/strong>: Potential to capture existing Strensiq patients seeking improved dosing convenience<\/li>\n\n\n\n<li><strong>Market Expansion<\/strong>: Addresses previously underserved adolescent and adult HPP population<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Comprehensive Phase III data package supports global regulatory submissions<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial potential for efzimfotase alfa. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,17,4621],"class_list":["post-62110","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-astrazeneca","tag-clinical-trial-results","tag-nyse-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy (ERT) for hypophosphatasia (HPP), demonstrating favorable safety and efficacy across pediatric and adult patient populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62110\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy (ERT) for hypophosphatasia (HPP), demonstrating favorable safety and efficacy across pediatric and adult patient populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62110\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T13:10:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T13:10:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62110#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62110\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations\",\"datePublished\":\"2026-04-01T13:10:26+00:00\",\"dateModified\":\"2026-04-01T13:10:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62110\"},\"wordCount\":440,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"Clinical trial results\",\"NYSE:\u202fAZN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62110#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62110\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62110\",\"name\":\"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-01T13:10:26+00:00\",\"dateModified\":\"2026-04-01T13:10:27+00:00\",\"description\":\"AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy (ERT) for hypophosphatasia (HPP), demonstrating favorable safety and efficacy across pediatric and adult patient populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62110#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62110\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62110#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy (ERT) for hypophosphatasia (HPP), demonstrating favorable safety and efficacy across pediatric and adult patient populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62110","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations","og_description":"AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy (ERT) for hypophosphatasia (HPP), demonstrating favorable safety and efficacy across pediatric and adult patient populations.","og_url":"https:\/\/flcube.com\/?p=62110","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T13:10:26+00:00","article_modified_time":"2026-04-01T13:10:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62110#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62110"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations","datePublished":"2026-04-01T13:10:26+00:00","dateModified":"2026-04-01T13:10:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62110"},"wordCount":440,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","Clinical trial results","NYSE:\u202fAZN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62110#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62110","url":"https:\/\/flcube.com\/?p=62110","name":"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-01T13:10:26+00:00","dateModified":"2026-04-01T13:10:27+00:00","description":"AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy (ERT) for hypophosphatasia (HPP), demonstrating favorable safety and efficacy across pediatric and adult patient populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62110#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62110"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62110#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62110"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62110\/revisions"}],"predecessor-version":[{"id":62111,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62110\/revisions\/62111"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}